CTX-177 (ONO-7018)
Immunology/Oncology
Phase 1Terminated partnership (Feb 2026)
Key Facts
Indication
Immunology/Oncology
Phase
Phase 1
Status
Terminated partnership (Feb 2026)
Company
About Chordia Therapeutics
Japanese biotech developing novel small molecule kinase inhibitors for oncology and immunology, with multiple clinical-stage assets.
View full company profile